The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Somatotropin Market Research Report 2024
Synopsis
The global Human Somatotropin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Somatotropin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Somatotropin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Human Somatotropin in Growth Hormone Deficiency (GHD) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Human Somatotropin include Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen and LG Life Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Somatotropin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Somatotropin.
Report Scope
The Human Somatotropin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Somatotropin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Somatotropin companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
Pfizer
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
GeneScience Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology
Segment by Type
Powder
Solvent
Segment by Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Somatotropin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Human Somatotropin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Somatotropin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Somatotropin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Human Somatotropin in Growth Hormone Deficiency (GHD) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Human Somatotropin include Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen and LG Life Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Somatotropin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Somatotropin.
Report Scope
The Human Somatotropin market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Somatotropin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Somatotropin companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
Pfizer
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
GeneScience Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology
Segment by Type
Powder
Solvent
Segment by Application
Growth Hormone Deficiency (GHD)
Turner Syndrome
Chronic Renal Insufficiency
Prader Willi Syndrome
Small for Gestational Age
SHOX Deficiency
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Somatotropin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Somatotropin Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Powder
1.2.3 Solvent
1.3 Market by Application
1.3.1 Global Human Somatotropin Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Growth Hormone Deficiency (GHD)
1.3.3 Turner Syndrome
1.3.4 Chronic Renal Insufficiency
1.3.5 Prader Willi Syndrome
1.3.6 Small for Gestational Age
1.3.7 SHOX Deficiency
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Somatotropin Market Perspective (2019-2030)
2.2 Human Somatotropin Growth Trends by Region
2.2.1 Global Human Somatotropin Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Human Somatotropin Historic Market Size by Region (2019-2024)
2.2.3 Human Somatotropin Forecasted Market Size by Region (2025-2030)
2.3 Human Somatotropin Market Dynamics
2.3.1 Human Somatotropin Industry Trends
2.3.2 Human Somatotropin Market Drivers
2.3.3 Human Somatotropin Market Challenges
2.3.4 Human Somatotropin Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Somatotropin Players by Revenue
3.1.1 Global Top Human Somatotropin Players by Revenue (2019-2024)
3.1.2 Global Human Somatotropin Revenue Market Share by Players (2019-2024)
3.2 Global Human Somatotropin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Somatotropin Revenue
3.4 Global Human Somatotropin Market Concentration Ratio
3.4.1 Global Human Somatotropin Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Somatotropin Revenue in 2023
3.5 Human Somatotropin Key Players Head office and Area Served
3.6 Key Players Human Somatotropin Product Solution and Service
3.7 Date of Enter into Human Somatotropin Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Somatotropin Breakdown Data by Type
4.1 Global Human Somatotropin Historic Market Size by Type (2019-2024)
4.2 Global Human Somatotropin Forecasted Market Size by Type (2025-2030)
5 Human Somatotropin Breakdown Data by Application
5.1 Global Human Somatotropin Historic Market Size by Application (2019-2024)
5.2 Global Human Somatotropin Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Human Somatotropin Market Size (2019-2030)
6.2 North America Human Somatotropin Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Human Somatotropin Market Size by Country (2019-2024)
6.4 North America Human Somatotropin Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Somatotropin Market Size (2019-2030)
7.2 Europe Human Somatotropin Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Human Somatotropin Market Size by Country (2019-2024)
7.4 Europe Human Somatotropin Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Somatotropin Market Size (2019-2030)
8.2 Asia-Pacific Human Somatotropin Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Human Somatotropin Market Size by Region (2019-2024)
8.4 Asia-Pacific Human Somatotropin Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human Somatotropin Market Size (2019-2030)
9.2 Latin America Human Somatotropin Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Human Somatotropin Market Size by Country (2019-2024)
9.4 Latin America Human Somatotropin Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Somatotropin Market Size (2019-2030)
10.2 Middle East & Africa Human Somatotropin Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Human Somatotropin Market Size by Country (2019-2024)
10.4 Middle East & Africa Human Somatotropin Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Detail
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Human Somatotropin Introduction
11.1.4 Novo Nordisk Revenue in Human Somatotropin Business (2019-2024)
11.1.5 Novo Nordisk Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Human Somatotropin Introduction
11.2.4 Pfizer Revenue in Human Somatotropin Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Human Somatotropin Introduction
11.3.4 Eli Lilly Revenue in Human Somatotropin Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 Merck Serono
11.4.1 Merck Serono Company Detail
11.4.2 Merck Serono Business Overview
11.4.3 Merck Serono Human Somatotropin Introduction
11.4.4 Merck Serono Revenue in Human Somatotropin Business (2019-2024)
11.4.5 Merck Serono Recent Development
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Detail
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche Human Somatotropin Introduction
11.5.4 F. Hoffmann-La Roche Revenue in Human Somatotropin Business (2019-2024)
11.5.5 F. Hoffmann-La Roche Recent Development
11.6 Ferring Pharmaceuticals
11.6.1 Ferring Pharmaceuticals Company Detail
11.6.2 Ferring Pharmaceuticals Business Overview
11.6.3 Ferring Pharmaceuticals Human Somatotropin Introduction
11.6.4 Ferring Pharmaceuticals Revenue in Human Somatotropin Business (2019-2024)
11.6.5 Ferring Pharmaceuticals Recent Development
11.7 GeneScience Pharmaceuticals
11.7.1 GeneScience Pharmaceuticals Company Detail
11.7.2 GeneScience Pharmaceuticals Business Overview
11.7.3 GeneScience Pharmaceuticals Human Somatotropin Introduction
11.7.4 GeneScience Pharmaceuticals Revenue in Human Somatotropin Business (2019-2024)
11.7.5 GeneScience Pharmaceuticals Recent Development
11.8 Ipsen
11.8.1 Ipsen Company Detail
11.8.2 Ipsen Business Overview
11.8.3 Ipsen Human Somatotropin Introduction
11.8.4 Ipsen Revenue in Human Somatotropin Business (2019-2024)
11.8.5 Ipsen Recent Development
11.9 LG Life Sciences
11.9.1 LG Life Sciences Company Detail
11.9.2 LG Life Sciences Business Overview
11.9.3 LG Life Sciences Human Somatotropin Introduction
11.9.4 LG Life Sciences Revenue in Human Somatotropin Business (2019-2024)
11.9.5 LG Life Sciences Recent Development
11.10 Sandoz International
11.10.1 Sandoz International Company Detail
11.10.2 Sandoz International Business Overview
11.10.3 Sandoz International Human Somatotropin Introduction
11.10.4 Sandoz International Revenue in Human Somatotropin Business (2019-2024)
11.10.5 Sandoz International Recent Development
11.11 Anhui Anke Biotechnology
11.11.1 Anhui Anke Biotechnology Company Detail
11.11.2 Anhui Anke Biotechnology Business Overview
11.11.3 Anhui Anke Biotechnology Human Somatotropin Introduction
11.11.4 Anhui Anke Biotechnology Revenue in Human Somatotropin Business (2019-2024)
11.11.5 Anhui Anke Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
